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Abstract
In ageing men testosterone levels decline, while cognitive function, muscle and bone mass, sexual
hair growth, libido and sexual activity decline and the risk of cardiovascular diseases increase. We
set up a double-blind, randomized placebo-controlled trial to investigate the effects of testosterone
supplementation on functional mobility, quality of life, body composition, cognitive function,
vascular function and risk factors, and bone mineral density in older hypogonadal men.
We recruited 237 men with serum testosterone levels below 13.7 nmol/L and ages 60–80 years.
They were randomized to either four capsules of 40 mg testosterone undecanoate (TU) or placebo
daily for 26 weeks. Primary endpoints are functional mobility and quality of life. Secondary
endpoints are body composition, cognitive function, aortic stiffness and cardiovascular risk factors
and bone mineral density. Effects on prostate, liver and hematological parameters will be studied
with respect to safety.
Measure of effect will be the difference in change from baseline visit to final visit between TU and
placebo. We will study whether the effect of TU differs across subgroups of baseline waist girth (<
100 cm vs. ≥ 100 cm; testosterone level (<12 versus ≥ 12 nmol/L), age (< median versus ≥ median),
and level of outcome under study (< median versus ≥ median).
At baseline, mean age, BMI and testosterone levels were 67 years, 27 kg/m2 and 10.72 nmol/L,
respectively.
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Background
In men after the age of 30–40, testosterone production
gradually declines which continuously persists into old
age [1,2]. Ageing in men is accompanied by a decrease in
muscle and bone mass, cognitive changes and decreased
libido and sexual activity, all of which have been sug-
gested to be related to the decrease in testosterone produc-
tion [3]. Recent research has provided evidence that
androgens play distinct roles in aspects of bone metabo-
lism[4], body composition such as muscle and fat mass
distribution [5,6], cognitive functioning [7], well-being
[8], cardiovascular diseases [9], prostate hyperplasia
[10,11]and in aspects of sexual behavior [12]. Since
androgens are associated with muscle function and with
cognitive functioning, it is reasonable to expect androgens
to be related to activities of daily living (ADL) as well [13].
The association of lower testosterone levels with age-
related conditions and the steady androgen levels decline
with aging stimulated further investigations to test useful-
ness and safety of androgen supplementation.
There are varying degrees of evidence regarding potential
risks and benefits of testosterone treatment in older men
[14]. The results of the Women Health Initiative (WHI)
randomized trial raised concerns about the risk-benefit
ratio of hormonal treatment [15]. Concerns regarding the
risks have focused primarily on the potential for increased
incidence of prostatic cancer, benign prostatic hyperplasia
[16], urinary obstruction [17], gynecomastia [18], sleep
apnea [19] and polycythemia [20]. Although androgens
are necessary for the development and normal function of
the human prostate, the role of testosterone in the pro-
gression of prostate cancer and benign prostatic hyperpla-
sia is not yet clear. Epidemiological studies have been
unable to relate the occurrence of benign prostatic hyper-
plasia and prostate cancer to androgens [21,22]. The cur-
rent opinion is that androgens are not causal but
permissive for the development of these diseases. With-
drawal of androgens leads to objective response rates of
metastatic lesions and of the primary tumor [23].
Recently, the issue whether physiological levels of andro-
gens are associated with prostate cancer risk seems to be
adequately refuted by the quantitative assessment of the
current evidence [22]. In spite of the circumstantial scien-
tific suggesting potential risks and limited support for
benefits, testosterone use has become increasingly popu-
lar in men of all ages.
The levels at which testosterone therapy might be indi-
cated in subjects with particularly low circulating levels
are also unclear. It is uncertain whether men who are at
the lower end of the normal range of testosterone produc-
tion would benefit from treatment. Therefore, we set up a
randomized trial with testosterone undecanoate. The key
objectives of the study are to treat men aged 60 years and
over, with low to low-normal testosterone levels, with tes-
tosterone undecanoate during six months and to study the
effect of this treatment on functional mobility, quality of
life, body composition, cognitive function, vascular age-
ing and bone mineral density. Safety assessments will per-
formed by measurements of the prostate, liver enzymes
and hematological parameters.
Testosterone undecanoate, the oral androgen to be used
in this intervention study, did not lead to signs of prostate
tumors in men who were followed-up for a minimum of
10 years [24]. With the androgens used in this study
androgen levels do not rise above normal. Most benefits
are expected on muscle strength and cognitive function-
ing. These areas are of major importance in determining
the ability of living independently at old age, and there-
fore elderly men are a potential subgroup that could ben-
efit from androgen supplementation.
Design and methods
The study is a single center randomized, placebo-control-
led, double-blind trial to assess the effects of supplemen-
tation with testosterone undecanoate on functional
mobility, quality of life, body composition, cognitive
function, vascular function and risk factors, and bone
mineral density in men, aged 60–80 years. The planned
number of study subjects is 240. After completion of the
baseline measurements subjects are randomized to four
capsules of 40 mg testosterone undecanoate (TU) or pla-
cebo daily for 26 weeks. The Institutional Review Board of
the University Medical Center Utrecht approved the study
protocol. All participants gave written informed consent
at screening visit.
Study population
The study was designed so that the study population
would comprise men in the lower half of the population
distribution of testosterone levels. Therefore, the exclu-
sion criteria were mainly limited to criteria indicating con-
traindications for testosterone, a high probability of
experiencing serious side effects, or a low likelihood of
completing the study.
In and exclusion criteria
Participants in this trial were healthy men aged 60 to 80
years (at the moment of inclusion), who lived in Utrecht
and vicinity and had a low normal testosterone concentra-
tion. Detailed information and definitions of the exclu-
sion criteria are displayed in Table 1. Men could not be
enrolled when they had a history of recent severe myocar-
dial infarction or cerebrovascular accident (< 6 months),
cardiac failure, unless medically treated and not sympto-
matic, history or presence of any malignancy within the
past 5 years, except for non-melanoma skin cancer, sub-
jects with ever history of testosterone (any hormone)Trials 2006, 7:24 http://www.trialsjournal.com/content/7/1/24
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dependent tumors (especially prostate or breast cancer),
serious liver disease, serious renal disease, hematological
abnormalities, epilepsy (or the use of anti-epileptic medi-
cation) or migraine more than once a month, diabetes
mellitus, presence of any disease or condition that is clin-
ically relevant and which might result in premature dis-
continuation, according to the opinion of the
investigator, corticosteroid use, use of testosterone esters
and alike substances within the past 60 days, increased
age-specified-PSA levels and prostate hypertrophy in med-
ical history (table 1).
Recruitment
Recruitment started in November 1st, 2003. Participants
were recruited by direct mailing to 8020 men aged 60 to
80 years whose addresses were randomly selected by the
municipal register of Utrecht. 1,846 men expressed inter-
est in the study by sending in a response-card. Men who
responded were explained the aim of the study and any
questions were answered. Also an information leaflet was
mailed. In this leaflet explanation was given regarding the
study and the in – and exclusion criteria protocol. After
one week of evaluation time 1,777 men were contacted by
telephone and invited to the information and screening
visit. Of these, 1030 responded positively and 747 refused
to participate. Also most of the exclusion criteria were
checked by telephone. Of those 1030 men, 346 were
excluded because of one or multiple exclusion criteria
(Fig. 1).
Information and screening visit
The selected 684 participants were asked to attend the
ambulatory clinic of the Julius Center for Health Sciences
and Primary Care of the University Medical Center
Utrecht, The Netherlands for more information about
study and screening. During this visit, after answering
remaining questions, the informed consent form was
signed. The participants filled in two questionnaires; the
Table 1: Exclusion criteria
Disease/Condition Definition
Recent severe myocardial infarction or cerebrovascular accident < 6 months
Cardiac failure, unless medically treated and not symptomatic
History or presence of any malignancy within the past 5 years, except 
for non-melanoma skin cancer. Subjects with ever history of 
testosterone (any hormone) dependent tumors.
Serious liver disease ASAT, ALAT, AF, γGT >3 times upper limit of reference value (ASAT: 
15–45 U/L; ALAT: 10–50 U/L; AF: 40–130 U/L ; γGT: 15–70 U/L:
Central Laboratory, UMC Utrecht)
Serious renal disease Serum creatinine levels > 180 mol/L)
Epilepsy (or the use of anti-epileptic medication) or migraine > once a 
month
Diabetes mellitus Diagnosed by physician or fasting glucose level of 6.9 mmol/L or higher 
(capillary)
Presence of any disease or condition that is clinically relevant and which 
might result in premature discontinuation, according to the opinion of 
the investigator.
Medication Definition
Corticosteroid use Orally: <6 months ago in dosage >7.5 mg a day, with the exception of 
short bouts of prednisone for the period of 7 days. Inhalation: <6 
months ago in the dosage of >800 g a day)
Use of testosterone esters and alike substances within the past 60 days
Conditions for which increase of androgen-like substances are contra-
indicated
PSA levels: age 60–69 years >4.5 μg/l;70 years and over >6.5 μg/L
Prostate hypertrophy in medical history Renal, liver function 
abnormalities or hematological abnormalities (Hb <7; Ht >0.50)
Prostate or breast cancerTrials 2006, 7:24 http://www.trialsjournal.com/content/7/1/24
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Participants flow diagram Figure 1
Participants flow diagram.
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Androgen Deficiency in Ageing Males (ADAM) question-
naire and the Ageing Males' Symptoms rating scale (AMS).
Remaining possible exclusion criteria were checked
through a medical history and blood examination in the
following order: fasting glucose level (capillary) of ≥ 6.9
mmol/L, (n = 35 exclusions), testosterone level higher
than the 50th percentile of the study population-based tes-
tosterone distribution (n = 279 exclusions), elevated PSA
level (age 60–69 years ≥ 4.5 μg/L; 70 years and above ≥ 6.5
μg/L (n = 30 exclusions), and serious liver- (> 3 times the
upper limit of reference value) or renal diseases (creati-
nine > 180 μmol/L) or hematological abnormalities
(hemoglobin ≤ 7.0 mmol/L, hematocrit ≥ 0.50) (n = 27
exclusions). There were still 47 participants who met one
of the other exclusion criteria and 25 participants who did
not want to start intervention for other reasons. If partici-
pants did not match the study-profile due to one or more
exclusion criteria, appropriate steps were undertaken to
refer (if necessary) the participant to his general practi-
tioner (n = 96). Major reasons for exclusion were testoster-
one level > cut-of-point, fasting glucose > 6.9 mmol/L or
an elevated PSA level. Also, a fasting blood sample for a
specific panel of laboratory assessments (including a spare
DNA blood sample) was taken. Finally, 241 men pro-
ceeded to the randomization visit.
Randomization visit
The randomization visit assessment was conducted when
all lab results were known and always within 4 weeks
from the information and screening visit. First, digital rec-
tal examination and trans-rectal ultrasound of prostate
were performed. If there was any suspicion regarding
prostate pathology, appropriate steps were undertaken to
refer the participant to its general practitioner or consult-
ing urologist. Four men were excluded for this reason. If
the rectal ultrasound did not show any signs of pathology
the participant continued the following baseline measure-
ments: medical history, family medical history, vital signs
(blood pressure, pulse), physical examination, anthro-
pometry measurements (height and body weight, waist-
and hip circumference, upper leg-, arm- and calf circum-
ference, sagittal abdominal diameter), International Pros-
tate Symptom Score (IPSS) questionnaire, functional
mobility measurements, bone mineral density measure-
ments via DEXA scan, health related quality of life ques-
tionnaires and utilities instrument, measuring cognition
(15-words test, Digit symbol Substitution test, Concept
Shifting Task test, the Benton Judgment of Line Orienta-
tion test and the Shephard rotation task), full body DEXA
scan (lean body mass, fat free and fat mass), Pulse Wave
Velocity (PWV), abdominal ultrasound for fat distribu-
tion.
Finally 237 men were eligible for randomization. These
subjects were randomly assigned to the intervention or
the placebo group. A randomization list was computer-
generated by Organon NV, Oss, The Netherlands. One
box with active medication and one box with placebo
medication were delivered at the UMC Utrecht Pharmacy
with the randomization list. Pharmacy personnel labeled
the jars for the participants and provided the study medi-
cation upon prescription of the trial physician. Randomi-
zation numbers were assigned to the subjects in orders of
enrolment into the trial.
Intervention
The intervention consisted of four capsules of 40 mg tes-
tosterone undecanoate (Andriol Testocaps®) provided by
Organon NV, Oss, the Netherlands. The placebo was an
identically looking and tasting capsule. The duration of
the intervention was 26 weeks in which participants had
to take the supplement on a daily basis. If for one reason
unbinding should be necessary during the course of the
trial, a backup hospital pharmacist was available who was
informed about the trial but not involved.
Control phone call (6 weeks)
All participants were called at 6 weeks after randomiza-
tion. At 6 weeks participants were asked about: Medical
history update, including co-medication and adverse
events. Also, they filled in the IPSS questionnaire.
Control visit (13 weeks)
During the intervention period of 26 weeks, subjects were
asked to visit our clinic at 13 weeks after randomization
(table 2). At 13 weeks the following measurement were
done: Medical history update, including co-medication,
adverse events, vital signs, (blood pressure, pulse), digital
rectal examination, IPSS questionnaire and laboratory
measurements (PSA, hematology, liver and renal func-
tions, spare blood sampling for additional investiga-
tions).
Final visit (26 weeks)
The final visit took place after 26 weeks of intervention. At
the final visit, all tests carried out at base-line were
repeated following the same procedures.
End point measurements
An overview of visits and measurements is shown in
Tables 2 and 3, respectively. Endpoints were assessed at
baseline and after 26 weeks. All the assessments took
place at the baseline randomization visit were repeated at
26 weeks.
Functional mobility measurement
We assessed the functional mobility by the use of timed
"Get Up and Go" test and a questionnaire for the ability
to perform activities of daily life the Stanford Health
Assessment Questionnaire (HAQ)[25,26]. Furthermore,Trials 2006, 7:24 http://www.trialsjournal.com/content/7/1/24
Page 6 of 12
(page number not for citation purposes)
skeletal muscle strength was assessed measuring handgrip
strength and isometric knee strength [27,28].
During the timed "Get Up and Go" test, the time taken by
an individual to rise from a standard chair, walk three
meters, turn around, return and sit down again was meas-
ured. The subject was requested to sit with his back against
the chair and arms resting on the chair and performs the
test three times. The fastest time was recorded in seconds.
The Stanford Health Assessment Questionnaire (HAQ)
has been widely used to measure functional status and
includes 24 questions grouped into 8 categories of 2, 3 or
4 ADL's. The categories were dressing, arising, eating,
walking, hygiene, reaching, gripping, and others. Partici-
pants responded to these questions by checking the level
of difficulty from 0 (without any difficulty) till 3 (unable
to do). If participants needed help from another person or
assistive devices for each of the ADL's the score raises auto-
matically to 2 (with much difficulty).
Handgrip strength was measured with the JAMAR®
dynamometer. The size of the grip was set so that the par-
ticipant felt comfortable. The participant was in standing
position his shoulder was adducted and neutrally rotated;
the arm was vertical and the wrist in a neutral position.
The participant squeezed the grip with maximal strength,
alternating the left and right hand. The unit was automat-
ically recorded the highest force exerted. Each test was
repeated at least 5 times until no further improvements
were seen. The best measure, recorded in kilograms, was
used for analysis.
Isometric knee extensor strength was measured with a
hand-held dynamometer. The participant was in a seated
position at a mat-table with the hip flexed to 90 degrees,
the knee stretched to 180 degrees and the legs dependent.
The dynamometer was applied perpendicularly to each
lower extremity just proximal to the malleoli. Participants
were instructed to take a second or two to come to come
to maximum effort and to then push as hard as possible
during another three seconds, while the investigator was
giving counterforce. Each test was repeated five times, and
if the examiner was not confident that a maximal effort
was reached one more effort was made. The best measure,
recorded in Newton, was used for analysis.
Table 2: Baseline characteristics of participants
Testosterone (n = 120) Placebo (n = 117)
Age (yr) 67.3 ± 5.1 67.5 ± 5.0
Weight (Kg) 86.1 ± 13.3 84.4 ± 13.6
Body Mass Index (kg/m2) 27.54 ± 3.85 27.20 ± 3.90
Smokers 21 (17.5) 15 (12.8)
Alcohol users 99 (82.5) 85 (77.3)
Hypertension 75 (62.5) 69 (59)
Systolic Blood Pressure (mm/Hg) 156.2 ± 23.2 151.1 ± 22.6
Diastolic Blood Pressure (mm/Hg) 89.8 ± 12.0 86.8 ± 11.7
Pulse Pressure (mm/Hg) 66.4 ± 15.9 64.3 ± 15.2
Pulse Wave Velocity (m/s) 10.00 ± 2.51 9.53 ± 2.66
Total Testosterone (nmol/L) 10.93 ± 2.06 10.50 ± 1.89
Free Testosterone (nmol/L) 0.22 ± 0.05 0.21 ± 0.05
Bioavailable Testosterone (nmol/L) 5.23 ± 1.15 5.04 ± 1.20
SHBG (nmol/L) 33.17 ± 10.59 32.90 ± 10.38
Albumin (g/L) 43.94 ± 2.31 43.80 ± 2.38
Cholestrol (mmol/L) 5.61 ± 0.99 5.50 ± 0.97
HDL (mmol/L) 1.16 ± 0.28 1.16 ± 0.29
LDL (mmol/L) 3.92 ± 0.91 3.80 ± 0.87
Insuline (mIU/L) 10.14 ± 9.50 8.73 ± 5.41
C-reactive proteine (mg/L) 4.27 ± 6.56 4.09 ± 6.97
PSA (μg/L) 1.54 ± 1.1 1.63 ± 1.1
Creatinine (μmol/L) 93.35 ± 18.0 93.72 ± 15.2
ASAT (U/L) 22.98 ± 8.1 24.21 ± 12.2
ALAT (U/L) 26.36 ± 11.0 26.74 ± 13.6
AF (U/L) 71.57 ± 19.2 69.91 ± 17.9
GGT (U/L) 29.51 ± 15.751 30.18 ± 19.9
Hemoglobine (mmol/L) 9.18 ± 0.5 9.14 ± 0.6
Hematocrit (%) 0.45 ± 0.0 0.45 ± 0.0
Prostate Volume (ultra sound) (cc) 28.20 ± 12.4 27.6 ± 9.8
IPSS 6.38 ± 5 6.50 ± 4.8
Values are means or numbers with S.D. or percentage in parentheses.Trials 2006, 7:24 http://www.trialsjournal.com/content/7/1/24
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Quality of life and well-being measurement
Quality of Life and well being was measured by the Short
Form-36 Health Survey as a generic QoL questionnaire
(SF-36) and the Herschbach-questionnaire as a hormone
specific questionnaire. The SF-36 is a questionnaire con-
sisting of questions regarding general health, ability to
perform physical activity and work, emotional problems
and assessment of his own health [29]. The Herschbach
questionnaire is a questionnaire translated from the ques-
tionnaire "Fragen zur Lebenszufriedenheit" (FLZ) accord-
ing to the method described by Henrich and Herschbach.
The questionnaire is divided in a "general" and a "health"
section, each including eight items. All items have been
evaluated on a 5-point scale according to their individual
importance (I) and degree of satisfaction (S). As a measure
of evaluation, a combination of importance and satisfac-
tion (I-1)*(S*2–5) will be used. In addition the sum of
the combination values will be calculated for each section
[30].
Sexual behavior and erectile dysfunction measurement
The 'Eleven questions about sexual functioning (ESF)
questionnaire, developed by the National Institute for
Social Sexual Research (Rutgers Nisso Group, Utrecht, The
Netherlands), has been used to assess sexual well being.
The questionnaire has 11 questions measuring sexual
drive (two questions); erectile function (three) and ejacu-
latory function (two), as well as assessing problems with
sex drive, erections, or ejaculation (three); and overall sat-
isfaction with sex life (one). Each question is scored on a
scale of 0–4, with higher scores indicating better function-
ing.
The Androgen Deficiency in Ageing Males (ADAM) and
the Ageing Males' Symptoms rating scale (AMS) question-
naires have been administered as well. The ADAM ques-
tionnaire contains 10 questions regarding the age-related
decline in androgens. All questions should be answered
yes or no. A positive questionnaire result, indicating an
androgen deficient state, is defined as a 'yes' answer to
question 1 or 7 or any 3 other questions [31]. AMS-ques-
tionnaire (Ageing Males' Symptoms rating scale) is a 17-
question questionnaire investigating age related health
complaints divided in three dimensions (psychological,
somatovegetative and sexual) of each 5 questions. Each
question can be scored from 1 (no symptoms) to 5 (very
severe symptoms), so a dimension can score from 5 to 25
points. Within each dimension, cumulative scores indi-
Table 3: Overview of the visits and measurements
Assessment Information visit and 
inclusion criteria
Screening and 
randomization visit
Phone call 6 weeks Visit 13 weeks Final visit 26 weeks
V1 V2 V3 V4
Check in & exclusion criteria X X
Informed consent X
Medical history (/update) X X X X X
Physical examination X X
Vital signs X X X
Anthropometry X X
Blood sample X X X
Glucose X X
DNA blood sample X
Testosterone X X
PSA X X X
Liver functions X X X
Renal functions X X X
Hematology X X X
Spare blood X X X
Rectal Ultrasound X X
Rectal Toucher X X X
DEXA full body X X
DEXA bone mineral density X X
Ultrasound abdominal fat mass X X
Pulse wave velocity (PWV) X X
Functional mobility X X
Cognition tests X X
Quality of Life (QoL) X X
ADAM/AMS questionnaire X X
Sexual functioning questionnaire X X
IPSS questionnaire X X X X
Randomization XTrials 2006, 7:24 http://www.trialsjournal.com/content/7/1/24
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cate the severity of the complaints on each territory; also
the cumulative of all dimensions indicate an overall view
of Ageing Males' Symptoms. Classification range spreads
from no impairment at all to severe impairment [32].
Body composition measurement
Body Composition was assessed by anthropometry (body
mass index (BMI), waist and hip girth, upper arm-, upper
leg and calf circumference and sagittal abdominal diame-
ter), full body DEXA scan (lean body mass, fat free- and fat
mass) and ultrasound of the abdominal fat mass.
BMI was calculated as the weight in kilograms divided by
the square of the height in meters, after taking of coat,
sweaters and shoes. All circumference measurements were
done with a standard household centimeter. Waist cir-
cumference was measured at the level of midway the dis-
tance between the lower rib and iliac crest, after normal
expiration without pressure of the centimeter at the skin.
The hip circumference was measured at the level of the
greater trochanter. The upper arm circumference was
measured at the non-dominant arm at the level of midway
between the tip of the acromnion and the olecranon. The
thigh circumference was measured just below the gluteal
fold of the left leg. Calf circumference was measured at the
level of the largest circumference of the left calf. The Sag-
ittal abdominal diameter (SAD) was measured using a
Holtain-Kahn (abdominal calliper (Holtain ltd., Cross-
well, UK) which allows a direct reading of the distance
between the subjects back and the front of the subjects'
abdomen. With subject in supine position a mark was
made halfway between the left and right iliac crest. The
lower arm of the caliper was inserted underneath the sub-
jects back and the upper arm was adjusted until touching
the abdominal wall at the level of the mid-abdominal
mark. The measurement was taken with a resting and at
the end of a normal expiration. The distance between the
subjects back and abdominal wall was measured on a cen-
timeter scale and round off to the nearest 0.1 cm. Since
with the abdominal subcutaneous fat tends to slip along
the flanks, when the subject is in supine position, the SAD
is an indirect measurement of the amount of visceral fat
mass.
Total body composition was measured with dual energy
X-ray absorptiometry (DEXA) using a Lunar prodigy®
DEXA instrument. Scanning was performed according to
the instructions of the manufacturer. After placement of
the subject on the table, there was scanning of the whole
subject from dorsal to ventral. Both legs and feet were
endorotated and fixed to on another. Calculations were
made regarding fat-mass, fat-free mass and lean body
mass [33].
Abdominal ultrasonography was performed in all abdom-
inal obese subjects with a Ultramark 9®. The distances
between the posterior edge of the abdominal muscles and
the lumbar spine or psoas muscles were measured using
electronical callipers. For all images the transducer was
placed on a straight line drawn between the left and right
mid-point of lower rib and iliac crest. The middle was
marked 10 cm from the left and right side. Distances were
measured from three different angles: medial, left and
right for intra-abdominal fat mass and medial for subcu-
taneous fat mass. Measurements were made at the end of
quiet expiration, applying minimal pressure without dis-
placement of intra-abdominal contents as observed by
ultrasound image [34].
Cognitive function measurement
Cognitive function was measured as follows. Verbal mem-
ory was tested with the Dutch version of the Rey Auditory
Verbal Learning Task. This is a test for long-term memory
retention. Fifteen words were read to the subject, who was
required to report as many words as he could remember
immediately after presentation. After a delay of 15 min (in
which another test, the Benton Judgment of Line Orienta-
tion, was administered), the subject was asked to recall as
many words as possible from memory [35].
Mental processing speed was tested with the "Digit Sym-
bol Substitution test". This is a sub-test from the Wechsler
Adult Intelligence Scale (WAIS) that covers general knowl-
edge. It measures cognitive and perceptual-motor process-
ing speed. The subject was given a code that pairs symbols
with digits. The test consists of matching as many series of
digits to their corresponding symbols as possible in 90 sec
[36].
The trail making test was used to test planning of move-
ment, vasomotor tracking, and processing speed. In this
test, pseudo-randomly placed circles with numbers (Trail
Making A1), with letters (Trail Making A2), and with both
numbers and letters (Trail Making B) have to be con-
nected with a line as fast as possible in a fixed order. In the
event of error, the subjects were immediately informed
and asked to restart from the point of error: this was done
with the timer left running. The time taken to complete
the trail without error was recorded [37]. The "Benton
Judgment of Line Orientation test" was used to measure
visual-spatial skills. This test measures basic perceptual
processes contributing to extra-personal spatial percep-
tion. The test requires the subject to identify which 2 of 11
lines presented in a semicircular array have the same ori-
entation in two-dimensional space as two-target lines
[38].
The visospatial performance was assessed by the Vanden-
berg and Kuse adaptation of Shepard and Metzler's three-Trials 2006, 7:24 http://www.trialsjournal.com/content/7/1/24
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dimensional mental rotations test [39]. This is the cogni-
tive task that has been most consistently associated with
testosterone levels. The test was consisted of 20 items in
which the subject was presented with a three-dimensional
geometric target line drawing and four test drawings, and
was required to indicate which two of four test drawings
depict the target drawing in rotated positions. Two paral-
lel test versions were made by taking the odd and even
items on time 1 (baseline) and time 2 (after intervention)
respectively (10 items for each test). These parallel ver-
sions have been shown to correlate strongly with each
other and to have a high reliability. Subjects were
instructed to "work as quickly as possible, but do not sac-
rifice accuracy for speed". They were allowed 10 minutes
to complete the test.
Aortic stiffness and cardiovascular risk factors 
measurements
Total cholesterol, HDL cholesterol and triglyceride were
measured by a timed endpoint method (Synchron LX®,
Beckman Coulter, Fullteron, California, USA) [40]. LDL
was calculated with the Friedewald equation [41]. Insulin
was measured by a solid-phase two site chemiliminesent
immunometric assay (IMMULITE 2000, Diagnostic Prod-
ucts Corporation, Los Angeles, California, USA). Serum
levels of highly sensitive CRP were measured using a near-
infrared particle immunoassay of the Synchron LX System
(Synchron LX®, Beckman Coulter, Fullteron, California,
USA).
Systolic and diastolic blood pressures and pulse were
measured in duplicate at the dominant arm with the sub-
jects in sitting position after 5 minutes of rest with an
automated and calibrated oscillometric device (Omron
Healthcare Europe, Hoofddorp, The Netherlands). Subse-
quently, the mean systolic and diastolic blood pressures
and mean pulse rate were calculated.
Aortic stiffness was determined by means of pulse wave
velocity. The Sphygmocor® system was used to non-inva-
sively measure stiffness of the aorta (Pulse wave velocity
system, PWV medical, Sydney, Australia) [42]. After 5 to
10 minutes rest of the subject in supine position, aortic
PWV was measured by sequentially recordings of arterial
pressure waveform at the carotid artery and the femoral
artery using a hand-held micromanometer-tipped probe
on the skin at the site of maximum arterial pulsation. Gat-
ing the recordings at those two sites to the electrocardio-
gram (ECG) allowed PWV to be measured. Recordings
were taken when a reproducible signal was obtained with
high amplitude excursion, i.e. usually 10 consecutive
beats to cover complete respiratory cycle. The system soft-
ware, using the R wave of a simultaneously recorded ECG
as a reference frame, was calculated the wave transit time.
A distance from the carotid-sampling site to the supraster-
nal notch and suprasternal notch to the femoral artery was
measured using a compass [43].
Bone mineral density measurement
Bone mineral density (BMD) was measured with dual
energy X-ray absorptiometry (DEXA) using a Lunar prod-
igy® DEXA instrument. Scanning was performed accord-
ing to the instructions of the manufacturer. BMD was
measured of lumbar vertebrae (L1–L4 individually and
together) and proximal femur (femoral neck, trochanter,
inter-trochanter, Ward's triangle and total hip, left-or right
if left not available). A T-score≤-2.5 denotes osteoporosis,
a T-score between -1 and -2.5 denotes osteopenia [44].
The DEXA scan was also used to measure total and trunk
lean body mass (see total body DEXA-scan). Quality
assurance, including calibration was performed routinely
every morning for DEXA (if that day a measurement is
planned), using the standard provided by the manufac-
turer [45].
Prostatic measurements
Effects on the treatments on the prostate were examined
by digital rectal examination, transrectal ultrasound of the
prostate and by monitoring serum prostate-specific anti-
gen (PSA) levels and by IPSS. The IPSS, developed by the
American Urological Association (AUA), contains seven
items that measure frequency and severity of urological
symptoms, together with an additional item measuring
the overall impact of these symptoms on quality of life.
Each of the seven symptom items has a response scale
with six choices, scored from 0 (absence of the symptom)
to 5 (symptom always present). Symptoms are considered
mild for scores between 0 and 7, moderate for scores
between 8 and 19, and severe for scores between 20 and
35 [46].
Digital rectal examination was performed at baseline, 13
weeks and at the end of treatment (26 weeks). Biplanal
transrectal ultrasonography of the prostate was performed
at baseline and at the end of treatment (26 weeks) with a
7-MHZ transrectal probe (Bruel and Kjaer Model 2110
Falcon). If rectal ultrasound was abnormal, patients were
excluded and referred for further evaluation. Serum pros-
tate specific antigen (PSA) levels were measured by an
immunnometric assay (IMMULITE® 2000 PSA, Diagnostic
Products Corporation, Los Angeles, California, USA) at
baseline, week 13 and at the end of the study. An increase
of > 1.4 μg/L between measurements at any time was
cause for concern. Abnormal values required repeat test-
ing; if values remained high, co-morbid illness was ruled
out. This was reason to exclude a patient and send to his
general practitioner.Trials 2006, 7:24 http://www.trialsjournal.com/content/7/1/24
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Laboratory measurements
Fasting blood samples were obtained between 8.00 and
11.00 AM to minimize diurnal variation. The level of total
testosterone and sex hormone binding globulin (SHBG)
were measured with a solid-phase, competitive, chemilu-
minescent enzyme immunoassay (IMMULITE ®  2000,
Diagnostic Products Corporation, Los Angeles, California,
USA) at baseline and at the end of the study. The intra-
assay coefficient of variation of this assay was 7.2% and
the inter-assay coefficient of variation was 8.2 % for testo-
sterone and 2.5% and 5.2 % for SHBG, respectively.
Hematology (hemoglobin and hematocrit) and routine
biochemistry (liver functions and creatinine) were meas-
ured by standard autoanalyzer methodologies (Synchron
LX®, Beckman Coulter, Fullteron, California, USA) at base-
line, after 13 weeks, and at the end of the study. During
the study, hemoglobin levels of ≤ 7 mmol/L, hematocrit
levels ≥ 0.50, liver function values ≥ three times normal
upper normal reference level (ASAT: 15–45 U/L; ALAT:
10–50 U/L; AF: 40–130 U/L ; γ-GT: 15–70 U/L), or creati-
nine levels of ≥ 180 μmol/l led to an extra blood check
after a week. If the values were still too high study partici-
pation was discontinued. All laboratory measurements
were done at the SHO laboratory, Velp, The Netherlands.
Adverse events
An adverse event (AE) was defined as any untoward med-
ical occurrence in a patient or clinical investigation subject
administered a pharmaceutical product and which did
not necessarily have a causal relationship with this treat-
ment. An AE could therefore be any unfavorable and
unintended sign (including an abnormal laboratory find-
ing), symptom, or disease temporarily associated with the
use of a medicinal report, whether or not considered
related to the medicinal product. Whether or not an
abnormal laboratory/vital sign were entered on the AE
form depends on whether or not the finding was clinically
relevant in the opinion of the investigator. Information
regarding AEs was obtained by questioning or examining
the subject. At each visit during the treatment period, all
new complaints and symptoms (i.e. those not existing
before the treatment period) were recorded (and coded)
on the AE Form. Pre-existing complaints or symptoms
that increased in intensity or frequency during the treat-
ment period were entered on the AE Form also. All AEs
were characterized in terms of their start and stop dates,
maximum intensity, action taken on trial medication,
relationship to trial medication, and subject outcome. If a
subject discontinued the trial because of an AE, this was
noted on the AE Form. Serious adverse events (SAE) forms
were supplied by Organon. If the AE meets the definition
of an SAE, the procedure for reporting SAEs was followed.
A serious adverse event (SAE) was defined as any unto-
ward medical occurrence that at any dose: resulted in
death, was life-threatening, required in-patient hospitali-
zation or prolongation of existing hospitalization,
resulted in persistent or significant disability or incapac-
ity, noted the term life threatening refers to an event in
which the patient was at risk of death at the time of the
event; it did not refer to an event, which hypothetically
might have caused death if it had been more severe. Med-
ical and scientific judgment was exercised in deciding
whether expedited reporting was appropriate in other sit-
uations, such as important medical events that might not
be immediately life-threatening or result in death or hos-
pitalization, but may jeopardized the patient or might
required intervention to prevent one of the other out-
comes listed in the definition above. These were consid-
ered serious. All SAEs were reported to the METC and to
Organon NV, Oss, the Netherlands. Every attempt was
made to obtain any relevant laboratory or hospital reports
that pertain to the SAE.
Compliance
Compliance was monitored by spare capsule counting at
each study visit. After finalization of the study serum tes-
tosterone concentrations were assessed in the final visit
blood samples as an extra check on compliance.
Power calculation
The pre-specified number of subjects was 240 in total, 120
in each intervention arm. This number was based on con-
ventional assumptions of α = 0.05 and β = 0.20, with-
drawal from intervention of 15% and an improvement of
25% on MHAQ and of 18% on the 15 Words test. These
improvements were realistic, since they have been previ-
ously reported in short-term small studies.
Data analysis
The primary analysis will be done by linear regression
analysis with change in outcome parameter between final
visit and baseline visit as the dependent and treatment
group as the independent variable. All analyses will be
based on an intention-to-treat approach (i.e., the inten-
tion-to-treat group will consist of all subjects, including
those who withdrew from blinded medication, who
received at least one dose of study drug and who had at
least one post-baseline assessment of the outcome varia-
ble). In addition to an intention-to-treat analysis, a per-
protocol analysis will be performed. The per-protocol
group will consist of all subjects from the intention-to-
treat group who did not have any major protocol viola-
tions. Furthermore, subgroup analysis will be performed
for the following predefined subgroups according to base-
line measurements: waist girth (< 100 cm versus ≥ 100
cm); testosterone level (< 12 versus ≥ 12 nmol/L), age (<
median versus ≥ median), and baseline level of outcome
under study (< median versus ≥ median). Differences
between final visit and baseline for continuous measures
were expressed as means and 95% confidence intervals;Trials 2006, 7:24 http://www.trialsjournal.com/content/7/1/24
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unpaired t-tests were used for testing. Level of significance
was set at P < 0.05. All analyses are performed with SPSS,
statistical software package, version 11.
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